Evaluation of Chemoresistance Markers in Women with Epithelial Ovarian Carcinoma

This publication has 18 references indexed in Scilit:

• Immunophenotype of Ovarian Cancer as Predictor of Clinical Outcome: Evaluation at Primary Surgery and Second-Look Procedure
  Gynecologic Oncology, 1998
• Oncogene Expression: Long-Term Compared With Short-Term Survival in Patients With Advanced Epithelial Ovarian Cancer
  Obstetrics & Gynecology, 1998
• Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian Carcinoma
  JNCI Journal of the National Cancer Institute, 1995
• The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
  Proceedings of the National Academy of Sciences, 1994
• Determination of Proliferation Index with MIB-1 in Advanced Ovarian Cancer Using Quantitative Image Analysis
  American Journal of Clinical Pathology, 1994
• Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
  Journal of Clinical Oncology, 1994
• Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis
  American Journal of Obstetrics and Gynecology, 1993
• Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms
  Cancer, 1992
• Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival
  The Journal of Pathology, 1990